E6/E7 Oncoproteins of High Risk HPV-16 Upregulate MT1-MMP, MMP-2 and MMP-9 and Promote the Migration of Cervical Cancer Cells

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2015 Jul 21

PMID 26191191

Citations 36

Authors

Dingjun Zhu

Mei Ye

Wei Zhang

Affiliations

Soon will be listed here.

Abstract

Background: E6 and E7 of high risk human papillomavirus 16 (HPV16) were reported to correlate with the cervical cancer (CC). And the presence of matrix metalloproteinases (MMPs) has also been indicated to be associated with CC.

Methods: The present study investigated the expression of MMPs (MT1-MMP, MMP-2 and MMP-9) in CC cells with HPV16-E6/E7 oncoprotein(s) negative or positive, and then determined the regulation of HPV16-E6/E7 oncoproteins on the expression of MMPs (MT1-MMP, MMP-2 and MMP-9) and the migration of cervical cancer Caski and SiHa cells with RNAi technology.

Results: It was demonstrated that the overexpression or the knockdown of HPV16-E6/E7 promoted or reduced MT1-MMP, MMP-2 and MMP-9 in CC cells. And the HPV16-E6, -E7 or -E6E7 influenced the migration of CC cells. The overexpression or the knockdown of them promoted or inhibited the migration of C33A or Caski/SiHa cells. Moreover, the chemical inhibition of MMP-2 or MMP-9 significantly reduced the migration of CC Caski or SiHa cells.

Conclusions: Our results demonstrated that the E6-HPV16 or E7-HPV16 promoted the activity of MMP-2/9, and contributed to the migration of cervical cells.

Citing Articles

Effects of Isoxazolyl Steroids on Key Genes of Sonic Hedgehog Cascade Expression in Tumor Cells.

Aleksandrova A, Mekhtiev A, Timoshenko O, Kugaevskaya E, Gureeva T, Gisina A Molecules. 2024; 29(17).

PMID: 39274874 PMC: 11396458. DOI: 10.3390/molecules29174026.

Role of Tumor-Associated Macrophages in Cervical Cancer: Integrating Classical Perspectives with Recent Technological Advances.

Choi Y, Lee D, Kim N, Seo I, Park N, Chong G Life (Basel). 2024; 14(4).

PMID: 38672714 PMC: 11051155. DOI: 10.3390/life14040443.

MiR-21 Regulates Growth and Migration of Cervical Cancer Cells by RECK Signaling Pathway.

Aguilar-Martinez S, Campos-Viguri G, Medina-Garcia S, Garcia-Flores R, Deas J, Gomez-Ceron C Int J Mol Sci. 2024; 25(7).

PMID: 38612895 PMC: 11012906. DOI: 10.3390/ijms25074086.

HPV E6/E7: insights into their regulatory role and mechanism in signaling pathways in HPV-associated tumor.

Peng Q, Wang L, Zuo L, Gao S, Jiang X, Han Y Cancer Gene Ther. 2023; 31(1):9-17.

PMID: 38102462 DOI: 10.1038/s41417-023-00682-3.

High-risk human papillomavirus prevalence among South African women diagnosed with other STIs and BV.

Qulu W, Mtshali A, Osman F, Ndlela N, Ntuli L, Mzobe G PLoS One. 2023; 18(11):e0294698.

PMID: 38032961 PMC: 10688634. DOI: 10.1371/journal.pone.0294698.

References

Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E . A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 1994; 370(6484):61-5. DOI: 10.1038/370061a0. View

Zhang W, Liu Y, Zhao N, Chen H, Qiao L, Zhao W . Role of Cdk1 in the p53-independent abrogation of the postmitotic checkpoint by human papillomavirus E6. J Virol. 2014; 89(5):2553-62. PMC: 4325723. DOI: 10.1128/JVI.02269-14. View

Boyer S, Wazer D, Band V . E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 1996; 56(20):4620-4. View

zur Hausen H . Papillomavirus infections--a major cause of human cancers. Biochim Biophys Acta. 1996; 1288(2):F55-78. DOI: 10.1016/0304-419x(96)00020-0. View

Smola-Hess S, Pahne J, Mauch C, Zigrino P, Smola H, Pfister H . Expression of membrane type 1 matrix metalloproteinase in papillomavirus-positive cells: role of the human papillomavirus (HPV) 16 and HPV8 E7 gene products. J Gen Virol. 2005; 86(Pt 5):1291-1296. DOI: 10.1099/vir.0.80551-0. View

Taxman D, Livingstone L, Zhang J, Conti B, Iocca H, Williams K . Criteria for effective design, construction, and gene knockdown by shRNA vectors. BMC Biotechnol. 2006; 6:7. PMC: 1409772. DOI: 10.1186/1472-6750-6-7. View

Kamangar F, Dores G, Anderson W . Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24(14):2137-50. DOI: 10.1200/JCO.2005.05.2308. View

Cardeal L, Brohem C, Correa T, Winnischofer S, Nakano F, Boccardo E . Higher expression and activity of metalloproteinases in human cervical carcinoma cell lines is associated with HPV presence. Biochem Cell Biol. 2006; 84(5):713-9. DOI: 10.1139/o06-084. View

Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2011; 127(12):2893-917. DOI: 10.1002/ijc.25516. View

10.

McCawley L, Matrisian L . Matrix metalloproteinases: they're not just for matrix anymore!. Curr Opin Cell Biol. 2001; 13(5):534-40. DOI: 10.1016/s0955-0674(00)00248-9. View

11.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

12.

Egeblad M, Werb Z . New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 2(3):161-74. DOI: 10.1038/nrc745. View

13.

Sheu B, Lien H, Ho H, Lin H, Chow S, Huang S . Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res. 2003; 63(19):6537-42. View

14.

Munger K, Phelps W, Bubb V, Howley P, Schlegel R . The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol. 1989; 63(10):4417-21. PMC: 251060. DOI: 10.1128/JVI.63.10.4417-4421.1989. View

15.

Woessner Jr J . Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991; 5(8):2145-54. View

16.

Au Yeung C, Tsang T, Yau P, Kwok T . Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway. Oncogene. 2011; 30(21):2401-10. DOI: 10.1038/onc.2010.613. View

17.

Rundhaug J . Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res., 9: 00-00, 2003. Clin Cancer Res. 2003; 9(2):551-4. View

18.

Wang P, Ko J, Yang S, Tsai H, Tee Y, Han C . Significant relation of tissue inhibitor of matrix metalloproteinase-2 and its combination with matrix metalloproteinase-2 to survival of patients with cancer of uterine cervix. Reprod Sci. 2011; 18(8):798-808. DOI: 10.1177/1933719111398143. View

19.

Li Y, Wu T, Zhang B, Yao Y, Yin G . Matrix metalloproteinase-9 is a prognostic marker for patients with cervical cancer. Med Oncol. 2012; 29(5):3394-9. DOI: 10.1007/s12032-012-0283-z. View

20.

Shaverdashvili K, Wong P, Ma J, Zhang K, Osman I, Bedogni B . MT1-MMP modulates melanoma cell dissemination and metastasis through activation of MMP2 and RAC1. Pigment Cell Melanoma Res. 2014; 27(2):287-96. DOI: 10.1111/pcmr.12201. View